Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025

Rhea-AI Summary

Lucid Diagnostics (NASDAQ:LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (NASDAQ:PAVM), announced its participation in the upcoming Cantor Global Healthcare Conference 2025.

Chairman and CEO Lishan Aklog, M.D. will engage in a fireside chat on September 5, 2025, at 8:35 AM EDT in New York. The 30-minute presentation will be available via webcast, with a replay accessible through the company's Investor Relations website for 30 days after the event.

Fireside chat with Chairman & CEO Lishan Aklog, M.D., scheduled for Friday, September 5, at 8:35 AM EDT

NEW YORK, Aug. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today announced Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 in New York, NY, on Friday, September 5, 2025, at 8:35 AM EDT.

Fireside Chat Details

Event: Cantor Global Healthcare Conference 2025

Date: Friday, September 5, 2025

Time: 8:35 AM – 9:05 AM EDT

Webcast: Register Here

The live and archived webcast of the fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website.  A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with GERD, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device - the first and only commercially available tools designed with the goal of preventing esophageal cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit luciddx.com and for more information about its parent company PAVmed, please visit pavmed.com.

Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics' common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics' products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics' clinical and preclinical studies; whether and when Lucid Diagnostics' products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics' products once cleared and commercialized; Lucid Diagnostics' ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics' control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics' future operations, see Part I, Item 1A, "Risk Factors," in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report.  Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-the-cantor-global-healthcare-conference-2025-302538501.html

SOURCE Lucid Diagnostics

FAQ

When is Lucid Diagnostics (LUCD) presenting at the Cantor Global Healthcare Conference 2025?

Lucid Diagnostics will present on Friday, September 5, 2025, from 8:35 AM to 9:05 AM EDT in New York.

Who will represent Lucid Diagnostics at the Cantor Healthcare Conference?

Dr. Lishan Aklog, Chairman and Chief Executive Officer of Lucid Diagnostics, will participate in a fireside chat at the conference.

How can investors access Lucid Diagnostics' presentation at the Cantor Conference?

Investors can access the presentation through a live webcast available on Lucid Diagnostics' Investor Relations website. A replay will be available for 30 days after the event.

What is Lucid Diagnostics' (LUCD) business focus?

Lucid Diagnostics is a commercial-stage medical diagnostics company focused on cancer prevention. It operates as a subsidiary of PAVmed Inc. (NASDAQ: PAVM).